• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Emotional distress following amyloid PET result disclosure: Heightened among those with cognitive symptoms.淀粉样蛋白PET结果披露后的情绪困扰:认知症状患者中更为严重。
Alzheimers Dement. 2025 Apr;21(4):e70121. doi: 10.1002/alz.70121.
2
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).¹⁸F - 氟代脱氧葡萄糖正电子发射断层显像(¹⁸F - FDG PET)用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2.
3
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代硼吡咯进行18F正电子发射断层显像以早期诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2.
4
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代甲磺酸去甲肾上腺素的18F正电子发射断层显像用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
5
Amyloid PET predicts longitudinal functional and cognitive trajectories in a heterogeneous cohort.淀粉样蛋白正电子发射断层扫描可预测异质性队列中的纵向功能和认知轨迹。
Alzheimers Dement. 2025 Mar;21(3):e70075. doi: 10.1002/alz.70075.
6
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
7
(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).(11)使用C-PIB-PET对轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆进行早期诊断。
Cochrane Database Syst Rev. 2014 Jul 23;2014(7):CD010386. doi: 10.1002/14651858.CD010386.pub2.
8
Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.获知结果的价值:轻度认知障碍患者淀粉样蛋白 PET 结果披露后的健康相关行为改变。
J Prev Alzheimers Dis. 2024;11(4):958-965. doi: 10.14283/jpad.2024.50.
9
Cerebral perfusion correlates with amyloid deposition in patients with mild cognitive impairment due to Alzheimer's disease.在因阿尔茨海默病导致轻度认知障碍的患者中,脑灌注与淀粉样蛋白沉积相关。
J Prev Alzheimers Dis. 2025 Feb;12(2):100031. doi: 10.1016/j.tjpad.2024.100031. Epub 2025 Jan 1.
10
Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.皮质 Tau 正电子发射断层扫描模式在临床前阿尔茨海默病患者中的差异。
JAMA Neurol. 2022 Jun 1;79(6):592-603. doi: 10.1001/jamaneurol.2022.0676.

本文引用的文献

1
Psychosocial implications of learning amyloid PET results in an observational cohort.学习淀粉样 PET 结果的心理社会影响:一项观察性队列研究。
Alzheimers Dement. 2024 Sep;20(9):6579-6589. doi: 10.1002/alz.14153. Epub 2024 Aug 11.
2
Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time.淀粉样蛋白 PET 披露在主观认知下降中的应用:患者随时间的体验。
Alzheimers Dement. 2024 Sep;20(9):6556-6565. doi: 10.1002/alz.14148. Epub 2024 Aug 1.
3
Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.获知结果的价值:轻度认知障碍患者淀粉样蛋白 PET 结果披露后的健康相关行为改变。
J Prev Alzheimers Dis. 2024;11(4):958-965. doi: 10.14283/jpad.2024.50.
4
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准:阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
5
Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.临床前期 AD 试验中不同种族和民族群体的披露后困扰。
Alzheimers Dement. 2024 Apr;20(4):2508-2515. doi: 10.1002/alz.13726. Epub 2024 Feb 8.
6
Psychosocial and Behavioral Outcomes for Persons With Cognitive Impairment and Caregivers Following Amyloid-β PET Scan Disclosure: A Systematic Review.认知障碍患者和照护者接受淀粉样蛋白 PET 扫描结果披露后的心理社会和行为结果:系统评价。
Alzheimer Dis Assoc Disord. 2023;37(3):246-258. doi: 10.1097/WAD.0000000000000569. Epub 2023 Jul 24.
7
Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.主观认知下降成人接受淀粉样蛋白正电子发射断层扫描成像结果披露后的心理症状分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2250921. doi: 10.1001/jamanetworkopen.2022.50921.
8
Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.向无认知障碍的研究参与者披露淀粉样蛋白成像结果的短期心理结果。
JAMA Neurol. 2020 Dec 1;77(12):1504-1513. doi: 10.1001/jamaneurol.2020.2734.
9
A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment.一项针对轻度认知障碍患者淀粉样蛋白正电子发射断层扫描结果披露的随机对照试验。
Alzheimers Dement. 2020 Sep;16(9):1330-1337. doi: 10.1002/alz.12129. Epub 2020 Jun 26.
10
How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment?患者及其护理伙伴对阿尔茨海默病评估的淀粉样蛋白-β PET 扫描结果报告的准确性如何?
J Alzheimers Dis. 2020;74(2):625-636. doi: 10.3233/JAD-190922.

淀粉样蛋白PET结果披露后的情绪困扰:认知症状患者中更为严重。

Emotional distress following amyloid PET result disclosure: Heightened among those with cognitive symptoms.

作者信息

Kim Jeong Eun, Ren Dianxu, Cohen Ann D, Lopez Oscar L, Lingler Jennifer H

机构信息

Health & Community Systems, University of Pittsburgh School of Nursing, Pittsburgh, Pennsylvania, USA.

Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

出版信息

Alzheimers Dement. 2025 Apr;21(4):e70121. doi: 10.1002/alz.70121.

DOI:10.1002/alz.70121
PMID:40189778
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11972971/
Abstract

INTRODUCTION

We examined differences in emotional distress following amyloid positron emission tomography (PET) results disclosure across the cognitive spectrum, including individuals who are cognitively unimpaired, with mild cognitive impairment (MCI), and dementia.

METHODS

Seventy-five participants from the University of Pittsburgh Alzheimer's Disease Research Center who completed baseline PET and an initial follow-up call were included in the analysis. Multiple linear regression was employed to examine differences in distress among diagnostic groups, as measured by Impact of Genetic Testing for Alzheimer's Disease (IGT-AD) adapted for amyloid PET.

RESULTS

Regression analysis revealed significant associations between diagnostic categories and emotional distress post-disclosure. Pairwise comparisons indicated that those with normal cognition experienced significantly lower distress compared to MCI and dementia groups, even after controlling for amyloid status.

DISCUSSION

Emotional distress following amyloid PET disclosure is significantly higher in cognitively symptomatic individuals compared to the asymptomatic, highlighting the need for tailored counseling and support to address the complex psychological effects of disclosure.

HIGHLIGHTS

Emotional distress was compared across cognitive categories outside trial settings Cognitively unimpaired individuals had significantly lower distress than impaired No significant difference in distress was found between MCI and dementia groups Depression and anxiety did not differ significantly across diagnostic categories.

摘要

引言

我们研究了在认知谱范围内,包括认知未受损、轻度认知障碍(MCI)和痴呆症患者,在披露淀粉样蛋白正电子发射断层扫描(PET)结果后情绪困扰的差异。

方法

分析纳入了匹兹堡大学阿尔茨海默病研究中心的75名参与者,他们完成了基线PET检查并进行了首次随访电话。采用多元线性回归来检验诊断组之间困扰程度的差异,通过适用于淀粉样蛋白PET的阿尔茨海默病基因检测影响(IGT-AD)来衡量。

结果

回归分析显示诊断类别与披露后情绪困扰之间存在显著关联。两两比较表明,即使在控制淀粉样蛋白状态后,认知正常者与MCI和痴呆症组相比,经历的困扰明显更低。

讨论

与无症状个体相比,认知有症状个体在披露淀粉样蛋白PET结果后的情绪困扰明显更高,这凸显了需要进行针对性咨询和支持,以应对披露带来的复杂心理影响。

要点

在试验环境之外的认知类别中比较了情绪困扰 认知未受损个体的困扰明显低于受损个体 MCI和痴呆症组之间在困扰方面未发现显著差异 抑郁和焦虑在各诊断类别之间没有显著差异